Free Trial

Teva Pharmaceutical Industries (TEVA) Stock Forecast & Price Target

$17.28
+0.18 (+1.05%)
(As of 07/12/2024 ET)

Teva Pharmaceutical Industries - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$18.56
7.38% Upside
High Forecast$24.00
Average Forecast$18.56
Low Forecast$11.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$18.56$15.88$13.78$10.44
Forecasted Upside7.38% Upside18.95% Upside26.03% Upside14.06% Upside
Get Teva Pharmaceutical Industries Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

TEVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TEVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Teva Pharmaceutical Industries Stock vs. The Competition

TypeTeva Pharmaceutical IndustriesMedical CompaniesS&P 500
Consensus Rating Score
2.78
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside7.35% Upside991.26% Upside9.18% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/10/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$22.00 ➝ $24.00+41.34%
7/10/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$20.00+26.58%
6/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$19.00 ➝ $23.00+39.82%
6/5/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$20.00 ➝ $21.00+24.78%
5/30/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$18.00 ➝ $21.00+25.60%
5/13/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$19.00 ➝ $20.00+23.08%
3/8/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Neutral$14.00+2.12%
2/5/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$10.00 ➝ $11.00-10.13%
12/18/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$13.00+30.26%
5/25/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight$10.00+32.10%
5/18/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform
11/7/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$11.00 ➝ $10.00+18.06%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:48 PM ET.

TEVA Forecast - Frequently Asked Questions

What is Teva Pharmaceutical Industries' forecast for 2024?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Teva Pharmaceutical Industries is $18.56, with a high forecast of $24.00 and a low forecast of $11.00.

Should I buy or sell Teva Pharmaceutical Industries stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TEVA shares.

Does Teva Pharmaceutical Industries's stock price have much upside?

According to analysts, Teva Pharmaceutical Industries's stock has a predicted upside of 23.74% based on their 12-month stock forecasts.

Has Teva Pharmaceutical Industries been upgraded by Wall Street analysts recently?

Over the previous 90 days, Teva Pharmaceutical Industries's stock had 1 upgrade by analysts.

What analysts cover Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has been rated by research analysts at Argus, Bank of America, Barclays, Jefferies Financial Group, Piper Sandler, and UBS Group in the past 90 days.

Do Wall Street analysts like Teva Pharmaceutical Industries more than its competitors?

Analysts like Teva Pharmaceutical Industries more than other "medical" companies. The consensus rating score for Teva Pharmaceutical Industries is 2.78 while the average consensus rating score for "medical" companies is 2.71. Learn more on how TEVA compares to other companies.


This page (NYSE:TEVA) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners